Co-morbidities in children and adolescents HIV-infected attending a paediatric HIV reference centre in São Paulo, Brazil
A.M. Silva1, M.R.D.O. Latorre1, L.F. Tanaka1, T.C.R. Oliveira1, C.L.A. Barbieri2, H.H.S. Marques2
1School of Public Heath - University of Sao Paulo, Epidemiology, São Paulo, Brazil, 2University of São Paulo, Instituto da Criança do Hospital das Clínicas, São Paulo, Brazil
Background: Due to increased survival of children and adolescents HIV-infected the occurrence of co-morbidities, not necessarily associated with death, has been increasing. We aimed to analyse mild and moderate co-morbidities at any time of follow up in children and adolescents HIV-infected, undergoing treatment at Children´s Institute (CI), in São Paulo city, Brazil, from 19991 to 2008.
Methods: 149 HIV-infected patients currently undergoing treatment at CI were analysed. Data were obtained from hospital records and the analysis were done using chi square test.
Results: Males represented 50.3% of patients. Age ranged from 2 to 19 years (mean 13 years) and most frequent age group was 9 to 12 years (53.7%), followed by age group 15 years and older (33.6%). Most patients (86.6%) had acquired HIV through mother-to-child-transmission. The most frequent co-morbidity was recurrent pneumonia (45.0%), followed by dislypidaemia (38.3%) e parotiditis (29.1%) (Figure 1). There is no statistical difference in prevalence of co-morbidities according to sex (p>0.05 for all).
Conclusions: Children and adolescents living with HIV/Aids are susceptible to various co-morbidities as a result of HIV infection itself and/or antiretroviral therapy. Therefore it is essential to be awake to these co-morbidities and its consequences for growth.
Back to the Programme-at-a-Glance